Advertisement
MENS vs VTGN
Which Stock Would AI Choose? Jyong Biotech (MENS) vs. Vistagen Therapeutics (VTGN) Stock Comparison
Key Takeaways
- Two clinical-stage biotechs, one shared challenge: Both MENS and VTGN are pre-revenue developers with no approved products, making their valuations dependent on clinical milestones and financing.
- Diverging clinical momentum: MENS has completed four Phase 3 trials for its lead candidate Botreso, while VTGN's lead candidate, fasedienol, missed its primary endpoint in two Phase 3 studies.
- Sharp valuation reset: Both stocks trade far below their 52-week highs, with VTGN down more than 80% following its December 2025 trial miss.
- Balance-sheet pressure: VTGN has reported a reduced cash runway and implemented a workforce reduction of roughly 20%, while MENS has carried a going-concern disclosure in its financial statements.
- Different market focus: MENS targets urology (benign prostatic hyperplasia and prostate cancer prevention), whereas VTGN targets central nervous system conditions such as social anxiety disorder.
- Sentiment gap: Current market positioning favors the stock with a less disrupted clinical narrative, a contrast reflected in recent relative performance.
- For more context, explore MENS Major News and MENS Today's Price Move, alongside VTGN Major News and VTGN Today's Price Move, to track the latest developments and daily price action.
- To see how automated systems are currently positioning across the market, explore Trending AI Robots.
Introduction
Investors evaluating speculative biotechnology names often compare companies at similar stages of development, and MENS and VTGN offer a useful side-by-side case study. Both are clinical-stage, pre-revenue businesses whose share prices hinge on clinical trial outcomes and cash management rather than earnings. Yet the two operate in different therapeutic areas and have experienced sharply different recent news flow. This stock comparison is most relevant to traders and investors who follow event-driven biotech catalysts, assess relative performance, and want a clearer view of how market positioning has shifted between two small-cap, high-volatility names.
MENS Overview and Recent Performance
MENS is the Nasdaq listing for Jyong Biotech Ltd., a Taiwan-based, science-driven biotechnology company developing plant-derived (botanical) drugs focused on urinary system diseases, with initial commercial ambitions across the United States, the European Union, and Asia. Its lead candidate, Botreso (also referenced as MCS-2 or API-1), is being developed for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), while a second candidate, PCP, targets prostate cancer prevention.
In recent weeks and months, Jyong Biotech has emphasized its commercial and regulatory strategy rather than releasing new efficacy data. The company has completed four Phase 3 clinical trials for Botreso across the United States and Taiwan and has signaled that it is accelerating New Drug Application (NDA) preparations and pursuing global licensing partnerships, including an initial licensing agreement and discussions with international pharmaceutical partners. Management has guided toward a combined NDA submission in the 2029-to-2030 timeframe, contingent on additional studies. On the sentiment front, the stock has traded well below its 52-week high after a broader pullback, with the company's financial statements carrying a going-concern disclosure tied to accumulated losses and the need to raise additional capital.
VTGN Overview and Recent Performance
VTGN is Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing "pherine" nasal-spray candidates designed to act through the nose-to-brain neural pathway. Its lead program, fasedienol, is being studied for the acute treatment of social anxiety disorder, with a separate candidate, refisolone, aimed at vasomotor symptoms such as hot flashes associated with menopause.
The dominant factor shaping recent performance has been clinical news. In December 2025, the company announced that the randomized portion of its PALISADE-3 Phase 3 study did not achieve its primary endpoint, triggering a decline of more than 80% in the share price in a single session. Subsequent analysis of PALISADE-4 also failed to meet its primary endpoint, and much of the company's subsequent commentary has centered on subgroup analyses rather than confirmatory results. Alongside these setbacks, Vistagen implemented a workforce reduction of approximately 20% to extend its cash runway and has disclosed a comparatively limited cash position relative to its quarterly burn. The shares have accordingly traded near the lower end of their 52-week range in recent weeks.
Trending AI Robots
Tickeron maintains a large library of automated trading tools, with hundreds of AI trading bots covering thousands of different tickers across varied timeframes, strategies, and risk profiles. Because not every bot suits every market regime, Tickeron curates a Trending AI Robots section that highlights the bots best aligned with current market conditions. These bots differ materially in trading style, holding period, win rate, and the specific tickers they monitor, so investors can compare performance statistics and select approaches that match their own objectives. Whether you track high-volatility biotech names or more liquid large caps, reviewing the Trending AI Robots page is a practical way to see how algorithmic systems are currently interpreting momentum and positioning.
Head-to-Head Comparison
The clearest contrast between these two names is the state of their clinical narratives. MENS has a lead asset that has completed multiple late-stage trials with a safety-focused story and is now pivoting toward regulatory and licensing execution, even though approval remains years away. VTGN, by contrast, is rebuilding confidence after two Phase 3 programs missed their primary endpoints, and its pipeline messaging has leaned on exploratory and subgroup analyses rather than confirmatory data.
Risk factors also differ. For MENS, the primary overhangs are execution timing, a distant NDA target, and financing needs. For VTGN, the overhangs are regulatory uncertainty, a shorter cash runway, a workforce reduction, and ongoing securities litigation following the share-price collapse. In terms of market positioning, both stocks are small-cap and volatile, but MENS has maintained a comparatively steadier, less event-disrupted profile in recent market activity, while VTGN has experienced more abrupt, headline-driven repricing.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely assign a relative edge to MENS over VTGN in the current environment. The more intact clinical narrative, completed Phase 3 studies, and a licensing-driven catalyst path offer a steadier trend foundation than a name working through back-to-back failed endpoints and financing constraints. That said, this is a probabilistic read rather than a definitive forecast: MENS still faces a long regulatory road and its own capital needs, and biotech sentiment can shift quickly on any single data release. The AI's tilt reflects relative positioning and catalyst quality, not a guarantee of near-term price direction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MENS is a Hold and VTGN is a Hold.
MENS saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for MENS moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 14 similar instances where the indicator exited the overbought zone. In 13 of the 14 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for MENS turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In 8 of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
MENS moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MENS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MENS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MENS as a result. In 13 of 18 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
Following a +15.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where MENS advanced for three days, in 71 of 80 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
MENS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (3.482). P/E Ratio (0.000) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. MENS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MENS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for VTGN turns negative, indicating new downward trend
VTGN saw its Momentum Indicator move below the 0 level on October 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 82 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
VTGN moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VTGN crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VTGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VTGN entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VTGN's RSI Indicator exited the oversold zone, 32 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for VTGN just turned positive on November 04, 2026. Looking at past instances where VTGN's MACD turned positive, the stock continued to rise in 37 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Following a +10.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where VTGN advanced for three days, in 190 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.297) is normal, around the industry mean (3.482). P/E Ratio (-0.099) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.764) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. VTGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VTGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VTGN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 91 | |
P/E GROWTH RATING 1..100 | 16 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| MENS | VTGN | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 90% | N/A |
| Momentum ODDS (%) | 1 day ago 72% | 3 days ago 90% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| Advances ODDS (%) | 11 days ago 89% | 4 days ago 79% |
| Declines ODDS (%) | 3 days ago 90% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 83% | N/A |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MENS’s FA Score shows that 0 FA rating(s) are green while VTGN’s FA Score has 1 green FA rating(s).
- MENS’s FA Score: 0 green, 5 red.
- VTGN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MENS’s TA Score shows that 3 TA indicator(s) are bullish while VTGN’s TA Score has 3 bullish TA indicator(s).
- MENS’s TA Score: 3 bullish, 5 bearish.
- VTGN’s TA Score: 3 bullish, 5 bearish.
Price Growth
MENS (@Biotechnology) experienced а -4.26% price change this week, while VTGN (@Biotechnology) price change was -2.67% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.35%. For the same industry, the average monthly price growth was -10.88%, and the average quarterly price growth was -18.54%.
Reported Earning Dates
VTGN is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-2.35% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MENS and
Correlation & Price change
A.I.dvisor indicates that over the last year, MENS has been loosely correlated with VTGN. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if MENS jumps, then VTGN could also see price increases.
| Ticker / NAME | Correlation To MENS | 1D Price Change % | ||
|---|---|---|---|---|
| MENS | 100% | +9.09% | ||
| VTGN - MENS | 59% Loosely correlated | -0.85% | ||
| KYTX - MENS | 44% Loosely correlated | +5.86% | ||
| FDMT - MENS | 33% Poorly correlated | +8.89% | ||
| IMNM - MENS | 30% Poorly correlated | +4.50% | ||
| BNTC - MENS | 29% Poorly correlated | +10.42% | ||
More | ||||
VTGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, VTGN has been loosely correlated with MENS. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if VTGN jumps, then MENS could also see price increases.
| Ticker / NAME | Correlation To VTGN | 1D Price Change % | ||
|---|---|---|---|---|
| VTGN | 100% | -0.85% | ||
| MENS - VTGN | 59% Loosely correlated | +9.09% | ||
| UNCY - VTGN | 43% Loosely correlated | +2.01% | ||
| KYTX - VTGN | 39% Loosely correlated | +5.86% | ||
| REPL - VTGN | 38% Loosely correlated | +7.99% | ||
| SYRE - VTGN | 38% Loosely correlated | +7.53% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IZRL | 25.63 | 0.63 | +2.52% |
| ARK Israel Innovative Technology ETF (IZRL) | |||
| DFSU | 46.74 | 0.07 | +0.15% |
| Dimensional US Sustainability Core 1 ETF (DFSU) | |||
| BBLB | 77.40 | 0.01 | +0.01% |
| JPMorgan BetaBuilders U.S. Treasury Bond 20+ Year ETF (BBLB) | |||
| GXLC | 92.75 | N/A | N/A |
| Global X U.S. 500 ETF (GXLC) | |||
| BASV | 30.95 | -0.06 | -0.19% |
| Brown Advisory Sustainable Value ETF (BASV) | |||